Comparison of preventive effect on cardiovascular events with different statins: The circle study

Circulation Journal

Volumn 75, Issue 8, 2011, Pages 1951-1959

  Maruyama, T ^a   Takada, M ^a   Nishibori, Y ^a   Fujita, K ^a   Miki, K ^a   Masuda, S ^a   Horimatsu, T ^a   Hasuike, T ^a  

^a Kawasaki Hospital   (Japan)

Author keywords

Cholesterol; High density lipoprotein; Low density lipoprotein; Secondary prevention; Statins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; INSULIN; LIPID; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; PROBUCOL; SPIRONOLACTONE; SULFONYLUREA; THIAZIDE DIURETIC AGENT; THIENOPYRIDINE DERIVATIVE;

ACUTE HEART INFARCTION; AGED; ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; JAPANESE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; AGED, 80 AND OVER; ANGIOPLASTY; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PYRROLES; QUINOLINES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79960823316     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1163     Document Type: Article

References (34)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
2. Sipahi I, Nicholls SJ, Tuzcu EM, Nissen SE. Coronary atherosclerosis can regress with very intensive statin therapy. Cleve Clin J Med 2006; 73: 937-944.
3. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
4. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004; 291: 1071-1080.
5. Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa- Toyama Y, Nishida M. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb 2010; 17: 436-451.
6. McTaggart F, Jones P. Effects of statins on high-density lipoproteins: A potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther 2008; 22: 321-338.
7. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499-508.
8. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: A complex process unrelated to changes in LDL-C: Analysis of the VOYAGER Database. J Lipid Res 2010; 51: 1546-1553.
9. Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008; 30: 1089-1101.
10. Miyauchi K, Daida H. Clinical significance of intensive lipid-lowering therapy using statins in patients with coronary artery disease. Circ J 2010; 74: 1718-1730.
11. Sakamoto T, Ogawa H. "Just make it lower" is an alternative strategy of lipid-lowering therapy with statins in Japanese patients. Circ J 2010; 74: 1731-1741.
12. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310.
13. Castelli WP Cholesterol and lipids in the risk of coronary artery disease: The Framingham Heart Study. Can J Cardiol 1988; 4(Suppl A): 5A-10A.
14. Oikawa S, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, et al. Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: Implication from Japan Lipid Intervention Trial (J-LIT). Atherosclerosis 2007; 191: 440-446.
15. Sukhija R, Aronow WS, Sureddi R, Aleti S, Molavi B, Sachdeva R, et al. Predictors of in-stent restenosis and patient outcome after percutaneous coronary intervention in patients with diabetes mellitus. Am J Cardiol 2007; 100: 777-780.
16. Arai H, Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, et al; JAPAN-ACS Investigators. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabeticpatients with acute coronary syndrome: Sub-analysis of JAPANACS study. J Atheroscler Thromb 2010; 17: 1096-1107.
17. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: Multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009; 73: 2110-2117.
18. Tani S, Watanabe I, Anazawa T, Kawamata H, Tachibana E, Furukawa K, et al. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol 2005; 96: 1089-1094.
19. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med 1977; 62: 707-714.
20. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(Suppl): S11-S20.
21. Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial. Lancet 2010; 376: 333-339.
22. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoproteincholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis. BMJ 2009; 338: b92.
23. Dean BB, Borenstein JE, Henning JM, Knight K, Merz CN. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Am Heart J 2004; 147: 966-976.
24. Yamashita S, Bujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, et al. Long-term probucol treatment prevents secondary cardiovascular events: A cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2008; 15: 292-303.
25. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
26. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304-1316.
27. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: Proatherogenic HDL: An evolving field. Nat Clin Pract Endocrinol Metab 2006; 2: 504-511.
28. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidasecatalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114: 529-541.
29. Barter PJ, Rye KA. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 2006; 259: 447-454.
30. Chen GL, Liu LW, Xie S, Liu H, Liu YQ, Li YS. High-density lipoproteinassociated factors apoA-I and serum amyloid A in Chinese non-diabetic patients with coronary heart disease. Chin Med J Engl 2010; 123: 658-663.
31. Tsukie N, Egashira K, Nakano K, Matoba T, Sunagawa K. Pitavastatin incorporated nanoparticle-eluting stents attenuate in-stent stenosis without anti-healing effects induced by sirolimus-eluting stents (Cypher) in porcine coronary artery model (abstract 4397). Circulation 2009; 120: S951.
32. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31: 224-230.
33. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
34. Garg S, Serruys PW, Coronary stents: Current status. J Am Coll Cardiol 2010; 56: S1-S42.